• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Barriers to medication access for opioid use disorder in adolescents and young adults

byAlexa FineandAlex Gipsman, MD
April 4, 2022
in Chronic Disease, Pediatrics, Psychiatry, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this systematic review of 37 studies, multiple barriers were identified in accessing medication for opioid use disorder for adolescents and young adults, including age, sex, race and ethnicity, geographic location, health and social system factors.

2. Adolescents and young adults may be more likely to be prescribed opioid medication deemed to have a lower abuse potential, such as opioid antagonists and partial agonists.

Evidence Rating Level: 3 (Average)

Study Rundown: Medications for opioid use disorders have been demonstrated to reduce deaths from opioid toxicity. Currently, a gap exists in understanding barriers to accessing medications for opioid use disorder in adolescents and young adults. This systematic review aimed to assess factors associated with access to medications for opioid use disorders among adolescents and adults between 10-30 years. 37 studies involving 179,785 adolescents and young adults were included (85% female, 84% white). Overall, adolescents and young adults were less likely than other age groups to access medications for opioid use disorder. In particular, adolescents were more likely to receive antagonist or partial agonist treatment instead of full agonist treatment. Decreased access was reported for individuals living in the southern United States. Low-income areas had overall better access to medications for opioid use disorders, however those in high-income areas were more likely to be prescribed medication. Health and social system factors such as long wait times, delayed prescriptions, and difficulty finding a prescriber were negatively associated with opioid medication access. Black and non-White race and Latino ethnicity were associated with decreased access to medications. Women were more likely to be prescribed medication for opioid use than men. Although study heterogeneity and predominantly white and female study population limits widespread applicability of the findings,  this review is helpful in identifying barriers to medication for opioid use disorder in adolescents and young adults that can be target for future interventions to improve treatment.

Click to read the study in JAMA Pediatrics  

Relevant Reading: Medication for adolescents and young adults with opioid use disorder

In-Depth [systematic review]: This systematic review included all empirical study designs, excluding case series/studies and reviews, from inception until May 2021. Medications for opioid use disorder were categorized as opioid agonists (e.g. methadone and buprenorphine), partial agonists (e.g. buprenorphine-naloxone), or antagonists (e.g. naltrexone). Access to opioid use medications included any assessment of availability, prescription or initiation of treatment. In total, 37 studies (17 cohort, 15 cross-sectional and 5 qualitative) published between 1992-2021 from multiple countries, primarily from the United States (n = 24), were included. A total of 179,785 adolescents and young adults were included, who were predominantly white (84%) and female (85%), with a mean age of 24.4. The majority of studies assessed access to methadone (n = 30), followed by buprenorphine (n = 26) and naltrexone (n = 10). Categories of variables assessed included age, involvement in the criminal justice system, geography, health and social system factors, personal health and social networks, race and ethnicity, sex, socioeconomic factors, and substance use type and behaviors.

RELATED REPORTS

Spectrophotometric assays for methadone may be effective for diversion control

Telemedicine bridge clinics may be helpful for opioid use disorder treatment

Prenatal medication for opioid use disorder helps discharge infants back to mothers

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: addiction medicineadolescent medicineopioid use disorder
Previous Post

Adherence to pre-treatment imaging guidelines for staging in rectal cancer is increasing, but a gap still remains

Next Post

Induction chemotherapy with paclitaxel, cisplatin and capecitabine showed promising clinical and safety response to treat advanced nasopharyngeal carcinoma

RelatedReports

Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription
Wellness

Spectrophotometric assays for methadone may be effective for diversion control

April 26, 2022
No obesity paradox found between BMI, stroke, and death
Chronic Disease

Telemedicine bridge clinics may be helpful for opioid use disorder treatment

April 25, 2022
Prenatal antidepressant exposure may increase risk of poor motor development
Chronic Disease

Prenatal medication for opioid use disorder helps discharge infants back to mothers

April 22, 2022
AAP opposes school-based drug testing of adolescents
Chronic Disease

Testing for sexually transmitted infections is infrequent among high school students in the United States

April 11, 2022
Next Post
Patient Basics: Nosebleed (Epistaxis)

Induction chemotherapy with paclitaxel, cisplatin and capecitabine showed promising clinical and safety response to treat advanced nasopharyngeal carcinoma

Steep decline in post-operative opioid prescriptions for common pediatric surgeries

#VisualAbstract: Neoadjuvant HD201 shows similar efficacy to referent trastuzumab for ERBB2-positive breast cancer

#VisualAbstract: Neoadjuvant HD201 shows similar efficacy to referent trastuzumab for ERBB2-positive breast cancer

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.